SLU-PP-332 500MCG ORAL TABLETS (Certificate of Analysis, Second Image)

Description

SLU-PP-332 500MCG ORAL TABLETS – METABOLIC PERFORMANCE & ENDURANCE RESEARCH

SLU-PP-332 Oral Tablets (500MCG each) by iLab Pharma are a precision-formulated PPARδ agonist designed for advanced research into lipid metabolism, oxidative energy pathways, and endurance optimization. This oral delivery format ensures consistent and accurate dosing for extended study protocols, allowing researchers to maintain steady experimental conditions.

By selectively activating PPARδ receptors, SLU-PP-332 supports increased fatty acid oxidation, improved mitochondrial efficiency, and enhanced metabolic flexibility in laboratory models. Its high receptor specificity minimizes off-target interaction, making it ideal for studies requiring targeted modulation of oxidative metabolism.

Each bottle contains 50 tablets of SLU-PP-332, manufactured by F40 Biotech under strict research-grade conditions and verified through third-party testing for purity, potency, and consistency. Tablets are securely packaged in tamper-proof containers to maintain stability and product integrity throughout storage and use.

Key experimental benefits include improved energy output, greater endurance capacity, and enhanced adaptation to high-performance energy demands in controlled research environments. SLU-PP-332 oral tablets are a valuable addition to metabolic, endurance, and performance-focused study designs.

Potential adverse effects in research settings are minimal but should be documented according to protocol. Product is not intended for medical use.

For research and educational purposes only. The customer assumes full responsibility for the proper handling and application of this product.